The importance of prognostic factors in cirrhosis  by Thalheimer, Ulrich & Burroughs, Andrew K.
The importance of prognostic factors in cirrhosis
paper on the effect of beta blockers in refractory ascites [6], i.e.,
the fact that higher portal pressure is related to increased mortal-
ity [7].
The use of albumin has important theoretical potential in cir-
rhosis [2]. It is therefore of vital importance that both authors and
reviewers are rigorous in the interpretation of studies evaluating
the therapeutic use of albumin.
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Letters to the EditorTo the Editor:
We read with great interest the study by Simón-Talero and col-
leagues [1]. They explore the potential beneﬁt of human albumin
infusions in the treatment of hepatic encephalopathy, adopting
an infusion regimen used with success in the treatment of spon-
taneous bacterial peritonitis (1.5 g/kg on day 1 and 1.0 g/kg on
day 3) and comparing it with an equivalent volume of normal sal-
ine solution.
Despite no difference in resolution of encephalopathy
between the two treatment arms (the primary end point), the
trial was terminated early after randomising 56 patients (out of
an initial calculated sample size of 124) due to an improved
90 day survival in the albumin group (69.2% vs. 40.0%), even
though this was one of the secondary end points.
Human albumin is not only quantitatively reduced in patients
with cirrhosis, but it also seems to be functionally impaired [2].
Administration of human albumin has been shown to be beneﬁ-
cial in patients with spontaneous bacterial peritonitis (SBP) [3],
hepatorenal syndrome [4], large volume paracentesis, and bacte-
rial infections other than SBP [5]. A survival beneﬁt in patients
with encephalopathy treated with albumin might therefore not
be entirely surprising, but the results of this study need to be
taken with great caution.
Apart from the fact (acknowledged by the authors) that mor-
tality was only a secondary end point, a closer examination of the
baseline characteristics yields further potentially confounding
factors. Most importantly, more than twice as many patients in
the normal saline arm had a history of SBP, gastrointestinal
bleeding, and hepatocellular carcinoma, and a substantially larger
number had a history of ascites and previous episodes of enceph-
alopathy. None of these differences reached statistical signiﬁ-
cance, but this is clearly linked to the low number of patients
in each arm. Unsurprisingly, more than twice as many patients
in the normal saline arm were on norﬂoxacin prophylaxis for
SBP and on beta-blockers. Finally, renal function was worse in
the normal saline group, with a mean creatinine of 1.4 mg/dl
vs. 0.9 mg/dl in the albumin arm; this reached statistical signiﬁ-
cance even despite the low numbers.
Episodes of spontaneous bacterial peritonitis, variceal bleed-
ing, hepatocellular carcinoma, and renal impairment are prognos-
tically adverse factors in patients with cirrhosis, and their
increased prevalence in the normal saline arm could certainly
have contributed to, if not explained, the difference in mortality
between the two groups. Indeed, the higher incidence of clinically
signiﬁcant portal hypertension in the normal saline group (as
suggested by the higher number of patients on beta blockers)
may well express the same bias present in a much debated recentJournal of Hepatology 2014 vol. 60 j 1325–1333
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